TB-500
TB-500 is a synthetic fragment of thymosin beta-4. Research studies it for cell migration and wound repair. Human evidence stays limited.
What the evidence shows, in short
- TB-500 is a fragment of thymosin beta-4, a 43-amino-acid actin-binding protein.
- Most published work is preclinical.
- The FDA reviewed TB-500-related bulk drug substances for the 503A Bulks List on 23 July 2026. The FDA evaluated it for wound healing.
- WADA prohibits TB-500 in sport.
- No regulator approved TB-500 for human use.
What TB-500 is
TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid actin-binding protein. Preclinical research focuses on cell migration, angiogenesis, and tissue remodeling. No regulator approved TB-500 for human use.
Mechanism (preclinical)
TB-500 binds G-actin and influences actin polymerization, a process central to cell motility and wound repair in preclinical systems.
What the published studies used
People search for a TB-500 dose. We do not give one, and here is why.
No human trial established a TB-500 dose. Published animal studies used a range of doses in different species and different injury models. Those numbers do not convert to a human dose, and no regulator reviewed them for human use.
We list the doses each study used, with the species and the route. Read them as study design, not as guidance.
| Study | Species | Route | Dose | Outcome | PMID |
|---|---|---|---|---|---|
| Dermal wound closure | Mouse | Subcutaneous | «verify» | Faster re-epithelialization vs. vehicle | «PMID» |
| Cardiac remodeling | Rodent | Intraperitoneal | «verify» | Improved repair markers after induced injury | «PMID» |
Read these as study design, not as guidance. No human trial established a dose for this compound.
Citations pending verification
Primary sources for this section are being verified before publication. A claim without a citation does not ship.
Primary research areas
Selected studies
Dermal wound closure (murine)
2012Faster re-epithelialization vs. vehicle.
Cardiac remodeling (animal)
2011Improved markers of repair after induced injury.
Regulatory status
United States. No FDA approval. The FDA Pharmacy Compounding Advisory Committee reviewed TB-500 on 23 July 2026 for wound healing.
Sport. WADA prohibits TB-500 in sport.
Sources
- FDA Pharmacy Compounding Advisory Committee — TB-500 briefing document.fda.gov/media/193349View source →
- WADA 2026 Prohibited List.View source →
If you source TB-500 for laboratory research
Buy only from a vendor that publishes a lot-matched COA from an independent laboratory. Check the lot number on the vial against the certificate. Read the HPLC result and the mass spectrometry result. Ask for the chromatogram.
Disclaimer
TB-500 carries no approval for human use in any major jurisdiction. This page reports published research. It is not medical advice and it is not a recommendation. Speak to a licensed clinician before any health decision.